Press release
Sjogren's Syndrome Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Sjogren's Syndrome Pipeline. Dive into DelveInsight's comprehensive report today! @ Sjogren's Syndrome Pipeline Outlook [https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Sjogren's Syndrome Pipeline Report
* In March 2025, Janssen Research & Development LLC announced a study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo. Sjogren's syndrome is a chronic, progressive autoimmune disease of unclear etiology typically originating in exocrine glands and capable of affecting the function of almost any organ system in the body.
* In March 2025, Amgen announced a study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS). The study will enroll 2 SS populations: Population 1 will include participants with moderate to high systemic disease activity; Population 2 will include participants with moderate to severe subjective symptoms.
* DelveInsight's Sjogren's Syndrome pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Sjogren's Syndrome treatment.
* The leading Sjogren's Syndrome Companies such as Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, Amgen, Rise Therapeutics and others.
* Promising Sjogren's Syndrome Pipeline Therapies such as Baricitinib, Hydroxychloroquine, HZN-1116, Nipocalimab, RSLV-132, Lanraplenib, Filgotinib and others.
Stay ahead with the most recent pipeline outlook for Sjogren's Syndrome. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Sjogren's Syndrome Treatment Drugs [https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Sjogren's Syndrome Emerging Drugs
* VAY736: Novartis
VAY736 (ianalumab) is a novel, intravenous, defucosylated, human IgG1/ monoclonal antibody that targets the human B cell-activating factor (BAFF) of the TNF family. The BAFF receptor is predominantly expressed on B cells and is critically involved in B cell maturation, activation, and survival. VAY736 targets the BAFF receptor and competitively inhibits BAFF binding to BAFF-R, thereby blocking BAFF-R-mediated signaling in B cells. It is also engineered to effectively eliminate B cells from circulation in vivo by antibody-dependent cellular cytotoxicity (ADCC). The ADCC activity of ianalumab is greatly enhanced by eliminating fucose residues from the carbohydrate moiety attached to the Fc part of the antibody. The molecule is being developed by Novartis in partnership with MorphoSys as an antibody-based therapy. The drug is currently in Phase III clinical studies for the treatment of Sjogren's Syndrome (SS).
* AMG 329: Amgen
AMG 329 is a fully human monoclonal antibody that binds and neutralizes the function of the FLT3-ligand, thereby reducing both conventional and plasmacytoid dendritic cells. The drug is currently in Phase II clinical studies for the treatment of Sjogren's Syndrome.
* R-2487: Rise Therapeutics
R-2487 is a targeted oral immune therapy that has the ability to induce T regulatory cell populations. R-2487 has a unique mechanism of action by which it can engage specific immune pathways that regulate tolerance and reset T regulatory deficiencies to reduce specific inflammatory cytokines that contribute to autoimmune disease. This mechanism is particularly important in the context of treating autoimmune disease. The drug is currently in Phase I clinical studies for the treatment of Sjogren's Syndrome.
The Sjogren's Syndrome Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Sjogren's Syndrome with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sjogren's Syndrome Treatment.
* Sjogren's Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Sjogren's Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sjogren's Syndrome market
Explore groundbreaking therapies and clinical trials in the Sjogren's Syndrome Pipeline. Access DelveInsight's detailed report now! @ New Sjogren's Syndrome Drugs [https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Sjogren's Syndrome Companies
Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, Amgen, Rise Therapeutics and others.
Unveil the future of Sjogren's Syndrome Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Sjogren's Syndrome Market Drivers and Barriers [https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Sjogren's Syndrome Pipeline Report
* Coverage- Global
* Sjogren's Syndrome Companies- Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, Amgen, Rise Therapeutics and others
* Sjogren's Syndrome Pipeline Therapies- Baricitinib, Hydroxychloroquine, HZN-1116, Nipocalimab, RSLV-132, Lanraplenib, Filgotinib and others.
* Sjogren's Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Sjogren's Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Sjogren's Syndrome Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Sjogren's Syndrome Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Sjogren's syndrome: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Sjogren's syndrome- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* VAY736: Novartis
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* AMG 329: Amgen
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* R-2487: Rise Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Sjogren's syndrome Key Companies
* Sjogren's syndrome Key Products
* Sjogren's syndrome- Unmet Needs
* Sjogren's syndrome- Market Drivers and Barriers
* Sjogren's syndrome- Future Perspectives and Conclusion
* Sjogren's syndrome Analyst Views
* Sjogren's syndrome Key Companies
* 27. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sjogrens-syndrome-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sjogren's Syndrome Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3966146 • Views: …
More Releases from ABNewswire
Best Gutter Cleaner in Sydney: GutterGorilla Raises the Standard for Professiona …
Best Gutter Cleaner in Sydney - GutterGorilla Continues to Deliver Reliable, Safe, and High-Quality Gutter Cleaning Services Across the Region
Best gutter cleaner in Sydney is a phrase more homeowners are using when talking about GutterGorilla, a growing local business focused on helping Sydney residents protect their properties through professional gutter cleaning and preventative maintenance. As heavy rain, seasonal storms and falling leaves continue to affect homes across New South Wales,…
Why UK Taxpayers Are Searching for the Best Free Tax Software in 2026
As HMRC continues to encourage online interaction, free tax software plays an important role in helping taxpayers adapt to digital filing. These tools lower the barrier to entry, reduce errors and help people understand what they owe or what they can claim back. Pie's approach reflects this shift, offering accessible tools built around real user needs and reinforcing its mission: "It's your money. Claim it."
LONDON, United Kingdom - As the…
Why EDDY Pump Is the Preferred Choice for Tunneling and Construction Projects
Image: https://www.abnewswire.com/upload/2026/02/4a61e58fc9bace5611bac16222cf30ce.jpg
Across Australia, large tunneling and underground construction projects are moving from planning into active execution. Metro rail expansions, road tunnels, water infrastructure, and utility corridors are being built in dense urban areas where space is limited, and delays are costly. On these sites, performance issues are rarely theoretical. If the equipment stops working, the job slows down immediately.
One of the most common pressure points on tunneling projects is material…
A Complete Checklist For First-Time Apartment Renter in 2026
Image: https://www.abnewswire.com/upload/2026/02/2d5388afc1b47f08a32ffc42a0c4093f.jpg
Being a first-time apartment renter is a big deal. It's exciting, maybe a little nerve-racking, but it's more than just picking a place to sleep. Leases, deposits, approvals, they can get confusing. But if you tackle things with a plan, you'll dodge the usual rookie mistakes and land a place that actually feels like home. That's what this guide is for: to help you settle in faster and with…
More Releases for Sjogren
Sjogren Syndrome Market Overview: Growth, Share, Value, Size, and Scope
The global Sjogren's Syndrome Market was valued at approximately USD 1.89 billion in 2023 and is projected to reach around USD 3.35 billion by 2032, growing at a compound annual growth rate (CAGR) of about 6.5% from 2024 to 2032.
Sjogren Syndrome Market Overview
The Sjogren's syndrome market is growing due to increasing awareness, improved diagnostic techniques, and a rising prevalence of autoimmune diseases worldwide. Sjogren's syndrome, which primarily affects middle-aged…
Hyaluronic Acid Market is Probable to Influence the Value of USD 16,313.95 Milli …
Data Bridge Market Research analyzes that the global hyaluronic acid market is expected to grow with a CAGR of 8.3% in the forecast period of 2023 to 2030 and is expected to reach USD 16,313.95 million by 2030.
Get a PDF Sample of the Hyaluronic Acid Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hyaluronic-acid-market
Hyaluronic acid is used primarily in beauty and skin care products. It provides speedy recovery to wounds, reduces face lines, wrinkles, and skin…
Sjogren’s Syndrome Market 2018 Growth, COVID Impact, Trends Analysis Report 20 …
The Sjogren’s syndrome is chronic autoimmune disease, in which the moisture-producing gland of the body is affected. It may be caused due to genetics, environmental changes or due to exposure to viruses or bacteria, which may result in primary or secondary Sjogren’s syndrome. The symptoms of this disease include Xerostomia (dry mouth), keratoconjunctivitis sicca (dry eye), skin dryness may result in lymphocytic infiltration and affects organs such as lungs, kidney,…
Covid-19 impact on - Sicca Syndrome (Sjogren) Market 2020 Industry Research, Sha …
The report endows with important information about the elements that are impacting and driving the sales of the Sicca Syndrome (Sjogren) Market. The section of competitive landscape keeps utmost importance in the report which consists of key market players functioning in the worldwide Healthcare industry. According to this report, several macroeconomic factors such as gross domestic product (GDP) and the increasing inflation rate are expected to affect directly or indirectly…
Sjogren‘s syndrome Market 2019 Industry Analysis, Segment & Forecast Up to 202 …
Global Sjogren‘s syndrome Industry
New Study On “2019-2023 Sjogren‘s syndrome Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast” Added to Wise Guy Reports Database
The Sjogren’s syndrome is chronic autoimmune disease, in which the moisture-producing gland of the body is affected. It may be caused due to genetics, environmental changes or due to exposure to viruses or bacteria, which may result in primary or secondary Sjogren’s syndrome. The symptoms of…
Xerostomia Therapeutics Market Outlook and Analysis to 2026 – Leading Top Comp …
The Report focuses on Xerostomia Therapeutics Market Asia Pacific Market, especially in China, Japan, Taiwan, Korea, Southeast Asia, India and Australia. As well as United Kingdom.
The Global Xerostomia Therapeutics Market Size is anticipated to reach over USD 822.14 million by 2026 according to a new research published by Polaris Market Research.
Xerostomia is also defined as dry mouth condition causing due to absent or reduced saliva. In general, xerostomia is not…
